N/A N=31 Radiosurgery in Treating Patients With Kidney Tumors
Kidney Cancer
Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=105 Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation
Living Donors · Nephrectomy · Kidney Transplantation
Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days
N/A N=80 Off Clamp Randomization
Renal Cancer · Renal Ischemia
Primary: Percent Change From Baseline in eGFR — -10.7; -9.4 percent change in eGFR
N/A N=11 Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants
Phase 2 N=291 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Childhood Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Clear Cell Sarcoma of the Kidney
Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199
N/A N=3 Robotic Single Port Donor Nephrectomy
Renal Transplant Donor of Left Kidney · Donor Nephrectomy · Robotic Surgery
Primary: Successful Completion of the Surgical Procedure — 3 Participants
Phase 2 N=25 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
N/A N=104 Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones
Urolithiasis · Urinary Lithiasis · Kidney Calculi
Primary: Stone Clearance — 76 participants
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
N/A N=26 Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Kidney Cancer
Primary: Safety of Sunitinib Malate (SM) — .350 proportion of participants
Phase 2 N=30 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Kidney Cancer
Primary: Response to Sunitinib Therapy — 13 participants
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
Phase 3 N=210 Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Renal Cancer
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR
Phase 3 N=1,943 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Clear Cell Renal Cell Carcinoma · Stage I Renal Cell Cancer AJCC v6 and v7 · Stage II Renal Cell Cancer AJCC v7
Primary: Disease-free Survival (DFS) — 5.8; 6.1; 6.6 years — p=0.80
Phase 3 N=1,499 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Kidney Cancer
Primary: 5-year Recurrence-free Survival (RFS) — 63; 67 percentage of paticipants
Phase 2 N=87 Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Kidney Cancer
Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants
N/A N=20 Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
Cancer of the Urinary Tract
Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants
N/A N=50 Rapid Renal Sympathetic Denervation for Resistant Hypertension
Hypertension, Resistant to Conventional Therapy
Primary: Acute Procedural Safety — 4 percentage of participants
N/A N=20 The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
Phase 2 N=24 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
Kidney Cancer
Primary: 3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope — 7.60 AU/second
N/A N=101 Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)
Kidney Stone · Renal Stone · Urolithiasis
Primary: Stone Free Rate (SFR) - Zero Fragments — 48; 49 % subjects
Phase 4 N=64 Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors
Skin Closure of Surgical Incisions by Tissue Glue vs Suture
Primary: Wound Healing by Numerical Scales for Rubor Postoperative Day 2. — 0.516; 0.984 units on a scale
Phase 3 N=864 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Kidney Cancer
Primary: Disease-free Survival — 192; 197 Participants — p=0.737
N/A N=618 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
N/A N=270 An Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies
Excision of Kidney
Primary: Proportion of Vessels Transected Requiring Intra-Operative Hemostatic Interventions — 0.1359; 0.1836 proportion of transected vessels
N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Phase 2 N=13 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=102 BMS 247550 to Treat Kidney Cancer
Renal Cell Carcinoma
Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants
Phase 4 N=111 Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy
Nephrectomy · Laparoscopic Donor Nephrectomy
Primary: Pain 'Right Now' — 2.4; 3.1 units on a scale